lung

1234567891011121314151617181920
Across
  1. 4. LIBTAYO biologic
  2. 6. LIBTAYO______ enhances patient access to LIBTAYO
  3. 8. color of LIBTAYO
  4. 10. organization of clinical trials
  5. 12. objective response rate. Duration of response. Complete response rate. Safety and tolerability.
  6. 13. criteria used to select patients for clinical trials
  7. 16. statistical method often used in evaluating pfs
  8. 17. the response restored by LIBTAYO
  9. 18. expresses programmed death receptor
  10. 19. method to confirm objective response rate (ORR)
  11. 20. profile in which adverse reactions are reported
Down
  1. 1. first line immune response
  2. 2. generates fully human therapeutic antibodies, including LIBTAYO
  3. 3. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  4. 5. action taken when a patient experiences a severe adverse reaction
  5. 7. 360 mg infusion, every 3 weeks
  6. 8. immune function inhibited by LIBTAYO
  7. 9. tumor staging criteria
  8. 11. administration method of LIBTAYO
  9. 14. approves drug indications
  10. 15. number of approved FDA indications for LIBTAYO